Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Myriad's myChoice To Be Used In More Cancer Clinical Trials

This article was originally published in The Gray Sheet

Executive Summary

Myriad is continuing its mission to expand its companion diagnostics reach by teaming up with Tesaro and Merck to evaluate their breast and ovarian cancer drugs, and expanding its partnership with Abbvie into lung cancer. .

Advertisement

Related Content

August M&A Analysis: Slow Month Highlighted By Unique Technologies
Myriad To Enter Neuroscience Market With $225m Assurex Acquisition
More Companion Diagnostic Deals For Qiagen And Myriad
Myriad Enters Companion Diagnostics Field With An FDA First

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register